The effect of quinolone-containing regimens for the treatment of Helicobacter pylori infection.
Phase 3
- Conditions
- Helicobacter pylori infection.Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters
- Registration Number
- IRCT2012101311101N1
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 140
Inclusion Criteria
All adult patients with gastrointestinal discomfort who refer to Namazi Hospital, Shiraz University of Medical Sciences. Exclusion criteria: Previous history of Helicobacter pylori eradication therapy; Consumption of antibiotics, bismuth salts or non-steroidal anti-inflammatory drugs during the past four weeks; previous gastric surgery; severe systemic diseases (such as liver cirrhosis or renal failure); sensitivity to each the antibiotics used in classical therapy; pregnancy and breastfeeding.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cure rate. Timepoint: 1 month after completion of drug therapy. Method of measurement: Urea Breath Test.
- Secondary Outcome Measures
Name Time Method Adverse drug reactions. Timepoint: after 2 weeks drug therapy. Method of measurement: patient evaluation.